Amgen's Repatha Meets Endpoints In GAUSS-3 Trial
This article was originally published in Scrip
Executive Summary
Results from Amgen's Phase III GAUSS-3 trial evaluating Repatha (evolocumab) in patients with high cholesterol have added to the growing evidence that the novel drug has the ability to reduce LDL (low-density lipoprotein) cholesterol in those patients who cannot tolerate statins or decrease levels of this 'bad' cholesterol through diet.